bc survivors who have never had Herceptin

1/3 of the women with bc detected have been HER2+. So is there going to be any formal discussion at all among oncs about the rather large group of bc survivors who have not had recurrence but finished chemo too soon to share in the combination treatment with herceptin?

So far I haven't seen even a vague discussion about any future clinical trials to document either the usefulness or lack of it for these survivors is even being contemplated by this convention of oncologists. Is there some valid reason for the silence about this?

I'm sure it takes time to analyze the data completely, but all of these oncs are going to have to answer that kind of question as soon as they pick up their phone.

As I understand it, the clinical trials involved were not based on that patient population, so waiting for a complete analysis of the data just puts off any documented solutions that would apply to that patient population.

AlaskaAngel